β-Cyclodextrins
(β-CDs) and β-CD-containing polymers
have attracted considerable attention as potential candidates for
the treatment of cholesterol-related metabolic and intractable diseases.
We have advocated the use of β-CD-threaded acid-degradable polyrotaxanes
(PRXs) as intracellular delivery carriers for β-CDs. As unmodified
PRXs are insoluble in aqueous solutions, chemical modification of
PRXs is an essential process to improve their solubility and impart
novel functionalities. In this study, we investigated the effect of
the modification of zwitterionic sulfobetaines on PRXs due to their
excellent solubility, biocompatibility, and bioinert properties. Sulfobetaine-modified
PRXs were synthesized by converting the tertiary amino groups of precursor
2-(N,N-dimethylamino)ethyl carbamate-modified
PRXs (DMAE-PRXs) using 1,3-propanesultone. The resulting sulfobetaine-modified
PRXs showed high solubility in aqueous solutions and no cytotoxicity,
while their intracellular uptake levels were low. To further improve
this system, we designed PRXs cografted with zwitterionic sulfobetaine
and cationic DMAE groups via partial betainization of the DMAE groups.
Consequently, the interaction with proteins, intracellular uptake
levels, and liver accumulation of partly betainized PRXs were found
to be higher than those of completely betainized PRXs. Additionally,
partly betainized PRXs showed no toxicity in vitro or in vivo despite
the presence of residual cationic DMAE groups. Furthermore, partly
betainized PRXs ameliorated the abnormal free cholesterol accumulation
in Niemann–Pick type C disease patient-derived cells at lower
concentrations than β-CD derivatives and previously designed
PRXs. Overall, the cografting of sulfobetaines and amines on PRXs
is a promising chemical modification for therapeutic applications
due to the high cholesterol-reducing ability and biocompatibility
of such modified PRXs. In addition, modification with both zwitterionic
and cationic groups can be used for the design of various polymeric
materials exhibiting both bioinert and bioactive characteristics.